Alzheimer's Disease Drug Development
Research and Development Ecosystem

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development.

Jeffrey Cummings (Edited by), Jefferson Kinney (Edited by), Howard Fillit (Edited by)

9781108838665, Cambridge University Press

Hardback, published 31 March 2022

574 pages
25.9 x 18.3 x 3 cm, 1.34 kg

'The book occupies a unique niche among similar titles in the area, presenting the state-of-the-art in Alzheimer's disease drug development from a drug discovery perspective, a clinical perspective, and a financial perspective.' Marc A. Ilies, Doody's Review

Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Part I. Advancing Alzheimer therapies in a collaborative science ecosystem
Part II. Non-Clinical assessment of Alzheimer candidate drugs
Part III. Alzheimer clinical trials
Part IV. Imaging and biomarker development in Alzheimer drug discovery
Part V. Academic drug development programs
Part VI. Public-Private partnerships in Alzheimer drug development
Part VII. Funding and financing Alzheimer drug development.

Subject Areas: Pharmaceutical technology [TDCW], Biotechnology [TCB], Neurosciences [PSAN], Nursing pharmacology [MQCM], Pharmacology [MMG], Neurology & clinical neurophysiology [MJN], Pharmaceutical industries [KNDP]